Controversies in Internal Medicine
August 11/25, 2003

Benefits of Combination Therapy of Insulin and Oral Hypoglycemic Agents

Author Affiliations

From the Baylor College of Medicine, Houston, Tex. The author has received research support from Bristol-Myers Squibb, GlaxoSmithKline, Tadeka, Novo Nordisk, Schering-Plough, Pfizer, Pharmacia & Upjohn, Novartis, Roche, Astra-Zeneca, and Restoragen; has acted as consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Novo Nordisk; and is a member of the speakers bureau of Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Novo Nordisk, Pfizer, Wyeth-Ayerst, and Aventis.




Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Intern Med. 2003;163(15):1781-1782. doi:10.1001/archinte.163.15.1781

IN THE 40 years since their introduction, oral hypoglycemic agents have become the cornerstone of pharmacologic therapy in type 2 diabetes mellitus. The 5 classes of oral agents now available are sulfonylureas, meglitinides, thiazolidinediones, biguanides, and α-glucosidase inhibitors. However, initial therapy with any of these agents ultimately fails as the result of a gradual loss of β-cell insulin secretory response to glucose. Treatment with an oral agent is often initiated as monotherapy; as glycemic control progressively worsens, a second agent is added in combination. The reported failure rates for single oral agents—5% to 20% per year—suggest that single oral therapy in type 2 diabetes succeeds for approximately 5 years. When therapy with multiple oral agents fails, exogenous insulin is required and is usually added to 1 or more of the existing regimen of oral agents. A large body of evidence suggests that insulin therapy should be initiated earlier in diabetes treatment and in combination with an oral agent to restore and maintain glycemic control, thus possibly reducing comorbidities of diabetes and sparing the remaining β-cell function.1